X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Religare Enterprises with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

RELIGARE ENT. vs INDOCO REMEDIES - Comparison Results

RELIGARE ENT.    Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    RELIGARE ENT. INDOCO REMEDIES RELIGARE ENT./
INDOCO REMEDIES
 
P/E (TTM) x -4.3 282.8 - View Chart
P/BV x 0.3 2.5 10.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 RELIGARE ENT.   INDOCO REMEDIES
EQUITY SHARE DATA
    RELIGARE ENT.
Mar-18
INDOCO REMEDIES
Mar-18
RELIGARE ENT./
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs238317 74.9%   
Low Rs34178 19.3%   
Sales per share (Unadj.) Rs126.2113.1 111.6%  
Earnings per share (Unadj.) Rs-58.24.5 -1,302.7%  
Cash flow per share (Unadj.) Rs-56.311.8 -477.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs82.273.2 112.2%  
Shares outstanding (eoy) m204.9592.15 222.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.12.2 49.2%   
Avg P/E ratio x-2.355.5 -4.2%  
P/CF ratio (eoy) x-2.421.0 -11.5%  
Price / Book Value ratio x1.73.4 48.9%  
Dividend payout %022.4 0.0%   
Avg Mkt Cap Rs m27,86322,830 122.0%   
No. of employees `000NA5.5 0.6%   
Total wages/salary Rs m4,9842,209 225.6%   
Avg. sales/employee Rs Th760,811.81,910.1 39,831.7%   
Avg. wages/employee Rs Th146,573.5405.0 36,193.9%   
Avg. net profit/employee Rs Th-350,735.375.5 -464,835.0%   
INCOME DATA
Net Sales Rs m25,86810,419 248.3%  
Other income Rs m1,06447 2,268.4%   
Total revenues Rs m26,93210,466 257.3%   
Gross profit Rs m-3,8561,349 -285.8%  
Depreciation Rs m376677 55.5%   
Interest Rs m12,610235 5,363.8%   
Profit before tax Rs m-15,779484 -3,260.0%   
Minority Interest Rs m1,5790-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2,27472 -3,141.3%   
Profit after tax Rs m-11,925412 -2,897.2%  
Gross profit margin %-14.912.9 -115.1%  
Effective tax rate %14.415.0 96.4%   
Net profit margin %-46.14.0 -1,167.0%  
BALANCE SHEET DATA
Current assets Rs m76,1605,373 1,417.5%   
Current liabilities Rs m72,7514,157 1,750.1%   
Net working cap to sales %13.211.7 112.9%  
Current ratio x1.01.3 81.0%  
Inventory Days Days068 0.0%  
Debtors Days Days4073 55.2%  
Net fixed assets Rs m15,0416,244 240.9%   
Share capital Rs m2,050184 1,112.1%   
"Free" reserves Rs m14,7976,566 225.4%   
Net worth Rs m16,8466,750 249.6%   
Long term debt Rs m58,2871,233 4,728.0%   
Total assets Rs m158,76212,363 1,284.2%  
Interest coverage x-0.33.1 -8.2%   
Debt to equity ratio x3.50.2 1,894.4%  
Sales to assets ratio x0.20.8 19.3%   
Return on assets %0.45.2 8.3%  
Return on equity %-70.86.1 -1,160.8%  
Return on capital %-2.19.0 -23.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m03,762 0.0%   
Fx outflow Rs m121,143 1.1%   
Net fx Rs m-122,619 -0.5%   
CASH FLOW
From Operations Rs m57,2271,227 4,663.2%  
From Investments Rs m-4,220-1,360 310.3%  
From Financial Activity Rs m-63,772-388 16,448.9%  
Net Cashflow Rs m-10,769-521 2,068.6%  

Share Holding

Indian Promoters % 50.9 59.2 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.9 12.5 7.2%  
FIIs % 15.3 6.0 255.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 32.9 22.4 146.9%  
Shareholders   26,518 12,805 207.1%  
Pledged promoter(s) holding % 68.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare RELIGARE ENT. With:   INDIABULLS FIN. SER.  NALWA SONS INV  TVS SRICHAKRA  TIMKEN INDIA  KOTHARI PRODUCTS  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

RELIGARE ENT. Announces Quarterly Results (3QFY19); Net Profit Up 75.2% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, RELIGARE ENT. has posted a net profit of Rs 103 m (up 75.2% YoY). Sales on the other hand came in at Rs 8 m (down 90.1% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.

CreditAccess Grameen IPO: Should You Apply to this Interesting Microfinance Play? (IPO)

Aug 7, 2018

Should you apply to the IPO of CreditAccess Grameen Ltd?

HDFC AMC IPO: Do Valuations Leave Enough on Table for Investors? (IPO)

Jul 20, 2018

Should you subscribe to the IPO of HDFC AMC Ltd?

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

RELIGARE ENT. SHARE PRICE


May 17, 2019 (Close)

TRACK RELIGARE ENT.

  • Track your investment in RELIGARE ENT. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RELIGARE ENT. 8-QTR ANALYSIS

COMPARE RELIGARE ENT. WITH

MARKET STATS